Retrospective Analysis Of Clinical Pathological Characteristics And Gene Mutation Site Frequency Of Non-small Cell Lung Cancer

Objective:By collecting the clinical data and high-frequency gene mutation sites of NSCLC patients,the relationship between the clinical pathological characteristics of NSCLC and the mutation sites of high-frequency genes was discussed.Analysing the expression of high-frequency gene mutation sites in non-small cell lung cancer at different ages and sexes.Analysing clinical data that may be related to gene mutation sites in NSCLC patients and providing a reference and extension direction for further research on targeted therapies of related genes.Methods:65 patients diagnosed with NSCLC parallel genetic testing between August,2017 and October,2021 were collected.At the same time,its clinical data were counted,including sex,age,smoking history,pathological classification and subtype,tumor stage,etc.Genetic testing was performed by high-throughput sequencing technology and contained common lung cancer oncogenic driver genes at least,such as EGFR,ALK,KRAS,ROS1,MET,HER-2,RET,BRAF,NRAS,PIK3CA,etc.Through comparative analysis and statistical methods,the correlation between the clinical data of patients with NSCLC and their gene mutation sites was studied.At the same time,the correlation between tumor stage,pathological classification,subtype,and lymph node metastasis and gene mutation sites was explored,which provided a theoretical basis for further research on related targeted therapies.Results:There are 44 cases of EGFR mutation,4 cases of ALK mutation,4 cases of KRAS mutation,2 cases of c-MET mutation,1 case of ROS1 mutation,1 case of RET mutation,1 case of BRAF mutation,and 2 cases of HER-2 mutation.Among patients with EGFR mutation,the mutation rate with a smoking history is 42.857%,and the mutation rate without a smoking history is 79.545%.The difference between the two groups is statistically significant(x~2=8.749,P<0.05).In terms of pathological types,the mutation rate of EGFR in the lung adenocarcinoma group is 74.138%,and the mutation rate in the non-adenocarcinoma group is 14.286%.The difference between the two groups is statistically significant(x~2=7.677,P<0.05).No correlation is found with the clinical features of the remaining gene mutations.The mean survival time of patients with EGFR mutation is 29.7 months,and the average survival time of patients with EGFR wild type is37.5 months.The difference between the two groups is not statistically significant.Clinical staging is a risk factor for tumor progression in patients with EGFR mutations(P<0.001).No statistically significant differences are found in the frequency of other gene mutation sites in clinical characteristics.Conclusion:EGFR is the most common and mutation-inducing driver gene in NSCLC patients.Then it is followed by ALK and KRAS genes.More non-smokers and adenocarcinoma patients are likely to develop EGFR mutations.The clinical staging become a risk factor for survival time.No difference in survival time between double gene mutation and single EGFR mutation is found.The rare gene mutations and the combination of multiple gene mutations found in this study do not exclude the existence of primary resistance mechanisms of EGFR.It provides direction for follow-up research.